These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25016707)

  • 1. Serum levels of tenascin-C variants in congestive heart failure patients: comparative analysis of ischemic, dilated, and hypertensive cardiomyopathy.
    Franz M; Berndt A; Grün K; Kuethe F; Fritzenwanger M; Figulla HR; Jung C
    Clin Lab; 2014; 60(6):1007-13. PubMed ID: 25016707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy.
    Terasaki F; Okamoto H; Onishi K; Sato A; Shimomura H; Tsukada B; Imanaka-Yoshida K; Hiroe M; Yoshida T; Kitaura Y; Kitabatake A;
    Circ J; 2007 Mar; 71(3):327-30. PubMed ID: 17322629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure.
    Fujimoto N; Onishi K; Sato A; Terasaki F; Tsukada B; Nozato T; Yamada T; Imanaka-Yoshida K; Yoshida T; Ito M; Hiroe M
    J Card Fail; 2009 Dec; 15(10):898-905. PubMed ID: 19944367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Serum Levels of Fetal Tenascin-C Variants in Patients with Pulmonary Hypertension: Novel Biomarkers Reflecting Vascular Remodeling and Right Ventricular Dysfunction?
    Rohm I; Grün K; Müller LM; Kretzschmar D; Fritzenwanger M; Yilmaz A; Lauten A; Jung C; Schulze PC; Berndt A; Franz M
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29117120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis.
    Franz M; Berndt A; Neri D; Galler K; Grün K; Porrmann C; Reinbothe F; Mall G; Schlattmann P; Renner A; Figulla HR; Jung C; Küthe F
    Int J Cardiol; 2013 Oct; 168(6):5344-51. PubMed ID: 23998545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.
    Ziffels B; Ospel J; Grün K; Neri D; Pfeil A; Fritzenwanger M; Figulla HR; Jung C; Berndt A; Franz M
    Dis Markers; 2016; 2016():3695454. PubMed ID: 27635109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy.
    Kitaoka H; Kubo T; Baba Y; Yamasaki N; Matsumura Y; Furuno T; Doi YL
    J Cardiol; 2012 Mar; 59(2):209-14. PubMed ID: 22218323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional heterogeneity of decreased myocardial norepinephrine and increased lipid peroxidation levels in patients with end-stage failing heart secondary to dilated or ischemic cardiomyopathy.
    Rochette L; Tatou E; Vergely C; Maupoil V; Bouchot O; Mossiat C; Jazayeri S; Benkhadra S; Brenot R; Girard C; David M
    J Heart Lung Transplant; 2008 Jul; 27(7):767-74. PubMed ID: 18582807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy.
    Niebroj-Dobosz I; Madej-Pilarczyk A; Marchel M; Sokołowska B; Hausmanowa-Petrusewicz I
    Clin Chim Acta; 2011 Aug; 412(17-18):1533-8. PubMed ID: 21596026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure.
    Sweet ME; Cocciolo A; Slavov D; Jones KL; Sweet JR; Graw SL; Reece TB; Ambardekar AV; Bristow MR; Mestroni L; Taylor MRG
    BMC Genomics; 2018 Nov; 19(1):812. PubMed ID: 30419824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy.
    McLeod CJ; Shen WK; Rea RF; Friedman PA; Hayes DL; Wokhlu A; Webster TL; Wiste HJ; Hodge DO; Bradley DJ; Hammill SC; Packer DL; Cha YM
    Heart Rhythm; 2011 Mar; 8(3):377-82. PubMed ID: 21070886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac unloading by LVAD support differentially influences components of the cGMP-PKG signaling pathway in ischemic and dilated cardiomyopathy.
    Persoon S; Paulus M; Hirt S; Jungbauer C; Dietl A; Luchner A; Schmid C; Maier LS; Birner C
    Heart Vessels; 2018 Aug; 33(8):948-957. PubMed ID: 29546540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial segmental thickness variability on echocardiography is a highly sensitive and specific marker to distinguish ischemic and non-ischemic dilated cardiomyopathy in new onset heart failure.
    Katikireddy CK; Acharya T
    Int J Cardiovasc Imaging; 2019 May; 35(5):791-798. PubMed ID: 30594979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.
    Sarli B; Topsakal R; Kaya EG; Akpek M; Lam YY; Kaya MG
    J Investig Med; 2013 Apr; 61(4):728-32. PubMed ID: 23429699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative Proteomic Analysis Reveals the Cytoskeleton Regulation and Mitophagy Difference Between Ischemic Cardiomyopathy and Dilated Cardiomyopathy.
    Liu M; Zhai L; Yang Z; Li S; Liu T; Chen A; Wang L; Li Y; Li R; Li C; Tan M; Chen Z; Qian J
    Mol Cell Proteomics; 2023 Dec; 22(12):100667. PubMed ID: 37852321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure.
    Lichtenauer M; Jirak P; Wernly B; Paar V; Rohm I; Jung C; Schernthaner C; Kraus J; Motloch LJ; Yilmaz A; Hoppe UC; Christian Schulze P; Kretzschmar D; Pistulli R
    Eur J Intern Med; 2017 Oct; 44():31-38. PubMed ID: 28579310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic values of serum tenascin-C in patients with ischaemic heart disease and heart failure.
    Yao HC; Han QF; Zhao AP; Yao DK; Wang LX
    Heart Lung Circ; 2013 Mar; 22(3):184-7. PubMed ID: 23177647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction.
    Sato A; Aonuma K; Imanaka-Yoshida K; Yoshida T; Isobe M; Kawase D; Kinoshita N; Yazaki Y; Hiroe M
    J Am Coll Cardiol; 2006 Jun; 47(11):2319-25. PubMed ID: 16750702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical study of remodeling of myocardial lymphatic and blood microvascular structures in terminal heart failure: differences between ischemic and dilated cardiomyopathy.
    Dashkevich A; Bloch W; Antonyan A; Goebel H; Fries JU; Schlensak C; Beyersdorf F; Geissler HJ
    Lymphology; 2010 Sep; 43(3):110-7. PubMed ID: 21226413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association among tenascin-C and NT-proBNP levels and arrhythmia prevalence in heart failure.
    Ozmen C; Deniz A; Deveci OS; Cagliyan CE; Celik AI; Yildiz İ; Yildiz PÖ; Demir M; Kanadasi M
    Clin Invest Med; 2017 Dec; 40(6):E219-E227. PubMed ID: 29256387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.